Category: Clinical Trials

Researchers are launching a clinical trial to investigate a new treatment approach for cancers linked to viral infections—a group of diseases that includes certain lymphomas, Kaposi sarcoma, and cancers of the head, neck, and reproductive organs. The study will evaluate the combination of pomalidomide, an oral immunomodulatory drug, and nivolumab, a widely used immunotherapy antibody, in adults whose cancers have not responded to standard treatments or who cannot undergo surgery.

What makes this trial especially encouraging is its inclusive design. It welcomes participants regardless of HIV status, including those with any CD4 T cell count—a population often excluded from cancer research due to complex treatment considerations. By opening enrollment to this broader group, the study aims to generate meaningful safety and efficacy data for patients who are frequently underrepresented in oncology trials, despite facing elevated risk for several virus-associated cancers.

The trial’s primary goal is to identify a safe and tolerable dosing schedule for the drug combination, given in 28-day treatment cycles for up to two years. Participants will be closely monitored through regular check-ins, imaging, lab work, and quality-of-life assessments, ensuring that safety remains a central focus throughout the study. For those with visible Kaposi sarcoma lesions, photographic tracking will help researchers assess treatment response over time.

Beyond direct patient care, the study incorporates a strong research component, collecting blood, saliva, and optional tissue samples to deepen scientific understanding of how these virus-driven cancers behave and respond to combination immunotherapy. This kind of translational research could inform future treatment strategies not just for the cancers studied here, but potentially for other virus-associated malignancies as well.

Trials like this represent an important step toward expanding treatment options for patients facing difficult-to-treat, virus-related cancers—particularly those who have exhausted other therapies or face significant risks from surgical intervention. As the study progresses, it may help pave the way toward less toxic, more effective care for a patient population with historically limited options. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

A new clinical trial is underway to explore whether an investigational therapy called telisotuzumab adizutecan can enhance the effectiveness of standard treatments for metastatic colorectal cancer (mCRC), one of the most commonly diagnosed cancers worldwide. The study, registered on ClinicalTrials.gov, will evaluate the combination of this investigational compound with well-established chemotherapy regimens including FOLFOX, bevacizumab, and panitumumab.

The trial will enroll approximately 390 adult participants across 100 sites globally, reflecting the scale of international collaboration being devoted to improving options for patients facing this diagnosis. Researchers will first determine optimal dosing through a careful escalation process, ensuring that the treatment is both tolerable and likely to be effective before moving into a randomized comparison phase. This methodical, safety-conscious approach is a hallmark of responsible drug development.

What makes this study particularly encouraging is its combination strategy—rather than testing a new compound in isolation, researchers are examining how it performs alongside therapies that are already approved and widely used for mCRC. This approach could potentially lead to enhanced treatment regimens that build on existing standards of care, offering new hope for patients whose options may currently be limited.

Participants in the trial will benefit from close monitoring throughout the process, including regular medical assessments, blood tests, and questionnaires designed to track both efficacy and safety. While the trial will run for approximately six years, reflecting the thorough nature of oncology research, this timeline also demonstrates the rigorous scientific standards being applied to ensure any potential benefits are well-documented before wider adoption.

Colorectal cancer remains a significant health challenge globally, making continued investment in innovative research like this especially valuable. Trials of this nature represent important steps in the ongoing effort to expand treatment possibilities for patients with advanced disease. As with all investigational therapies, telisotuzumab adizutecan will need to demonstrate both safety and efficacy through this rigorous trial process before any conclusions can be drawn about its potential benefits. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Chronic widespread pain affects a significant number of people living with HIV, often diminishing quality of life even when the virus itself is well-managed. A newly registered clinical trial is taking a closer look at the biological roots of this pain, with a particular focus on the body’s own peptide systems.

Researchers are investigating whether reduced production or release of endogenous opioid peptides—naturally occurring molecules that help regulate pain sensitivity—by peripheral immune cells may play a key role in the heightened pain responses seen in some people with HIV. Endogenous opioid peptides are part of the body’s built-in pain-management system, and understanding how their function may be altered in this population could reveal important clues for future treatment strategies.

What makes this research particularly encouraging is its potential to shift how chronic pain in HIV is understood and eventually treated. Rather than relying solely on general pain management approaches, identifying the specific peptide-related mechanisms at play could pave the way for more targeted therapeutics designed to restore healthy immune-nervous system communication and pain regulation.

This type of mechanistic research is an important early step. By clarifying how immune cells and opioid peptides interact in the context of HIV, scientists hope to lay the groundwork for future therapies that could offer more effective and personalized relief for patients dealing with persistent pain. Studies like this reflect the broader promise of peptide science: not just in treating disease directly, but in helping researchers understand the body’s own regulatory systems well enough to support and enhance them.

As this trial progresses, it adds to a growing body of work exploring how peptides influence pain, immunity, and overall wellbeing. Continued research in this area could eventually benefit not only people living with HIV, but potentially others experiencing chronic pain linked to immune system changes.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

A new clinical trial is underway to evaluate epcoritamab, an investigational subcutaneous therapy, for adults in China living with B-cell Non-Hodgkin Lymphoma. This aggressive form of cancer affects immune cells, and the study aims to bring a promising treatment option to a broader population of patients who may benefit from expanded access to innovative therapies.

The trial, registered on ClinicalTrials.gov, will enroll approximately 66 participants across 21 sites throughout China. Researchers are exploring three treatment approaches: epcoritamab as a standalone monotherapy, and two combination regimens pairing epcoritamab with well-established standard-of-care chemotherapy protocols—R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and R2 (rituximab plus lenalidomide). This multi-arm design allows scientists to gather valuable data on how epcoritamab performs both independently and alongside existing treatments that many oncologists already trust.

Epcoritamab represents an exciting category of cancer therapy known as bispecific antibodies, which work by helping the immune system’s own T-cells recognize and attack cancer cells more effectively. By administering the drug subcutaneously rather than through more invasive methods, researchers are also exploring ways to potentially make treatment more convenient for patients managing a serious illness.

Throughout the study, participants will receive close monitoring through regular medical assessments, blood tests, and questionnaires, ensuring that both safety and treatment response are carefully tracked. This rigorous oversight reflects the thorough, patient-centered approach that characterizes modern clinical research, helping to build a comprehensive safety and efficacy profile for this therapy in a new patient population.

The expansion of this trial into China is particularly encouraging news, as it means patients in this region will have the opportunity to access a cutting-edge investigational therapy that has shown promise in earlier research. Studies like this one are essential steps in the journey toward potentially new treatment options for people facing B-cell Non-Hodgkin Lymphoma, and successful results could pave the way for broader availability down the line.

This article is for informational purposes only and does not constitute medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

A new Phase III clinical trial is underway to evaluate the efficacy and safety of Sinotropin AQ, a human growth hormone (hGH) injection, in children diagnosed with Idiopathic Short Stature (ISS). This multicenter, randomized, active-controlled study represents an important step forward in expanding treatment options for children whose growth patterns fall outside typical developmental ranges without an identifiable medical cause.

The trial is designed as a non-inferiority study, meaning researchers will compare the effectiveness of Sinotropin AQ against an already established active comparator treatment. Over a 52-week treatment period, participants will be randomized to receive either the study drug or the comparator, with researchers closely monitoring height velocity—measured in centimeters gained per year—as the primary marker of treatment success. The study drug will be administered subcutaneously once daily at a dose of 0.15 IU/kg, following established growth hormone dosing protocols.

Idiopathic Short Stature affects children whose height falls significantly below average for their age and sex, without a clear underlying cause such as growth hormone deficiency or chronic illness. For families navigating this diagnosis, having well-studied, effective treatment options can make a meaningful difference in a child’s development and quality of life. This trial’s rigorous, controlled design reflects a thoughtful approach to generating reliable evidence about whether this particular hGH formulation can safely and effectively support healthy growth in this population.

What makes this study particularly encouraging is its structure: by using an active comparator rather than a placebo, researchers ensure that all participating children receive some form of established treatment throughout the trial, while still gathering valuable comparative data. This approach balances scientific rigor with ethical consideration for participants. If the results demonstrate that Sinotropin AQ performs comparably to existing treatments, it could potentially offer clinicians and families an additional validated option for managing ISS.

As this Phase III trial progresses, it adds to the broader body of research supporting growth hormone therapies for pediatric growth conditions. Continued investment in well-designed clinical trials like this one helps ensure that treatment decisions for children are grounded in solid, reproducible evidence. This information is provided for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature

Gan & Lee Pharmaceuticals has officially begun a Phase 1 clinical trial in the United States for ASC36, an investigational oral amylin peptide being developed as a potential treatment for obesity. This milestone adds another promising candidate to the rapidly evolving landscape of peptide-based metabolic therapies, which have already transformed treatment options for weight management and related conditions.

Amylin is a naturally occurring hormone that works alongside insulin to help regulate appetite and glucose levels. By targeting amylin receptor pathways, ASC36 aims to complement or potentially differentiate itself from the GLP-1 class of drugs that have dominated headlines in recent years. Notably, the fact that ASC36 is being developed as an oral formulation—rather than requiring injections—could represent a meaningful convenience advantage for patients if the drug continues to show safety and efficacy in future trials.

Oral peptide delivery has historically been a significant technical challenge, since peptides are often broken down before they can be effectively absorbed by the body. Companies that succeed in developing effective oral versions of these therapies could greatly expand access and improve comfort for patients who prefer avoiding injections altogether. Gan & Lee’s move to bring ASC36 into human trials suggests confidence in their formulation approach and its early preclinical data.

This Phase 1 trial will primarily focus on assessing the safety, tolerability, and pharmacokinetics of ASC36 in human participants—an essential first step before any determination can be made about its long-term effectiveness for obesity treatment. While it is still early in the clinical development process, the initiation of this trial reflects the continued momentum and innovation happening within the peptide therapeutics field, particularly as researchers explore new ways to make metabolic treatments more accessible and easier to use.

As the obesity treatment market continues to expand, differentiated approaches like oral amylin peptides could offer valuable additional options for patients and healthcare providers alike. True North Labs will continue to monitor the progress of ASC36 and similar peptide innovations as they move through the clinical trial pipeline.

This article is for informational purposes only and does not constitute medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Gan & Lee’s Obesity Drug ASC36 Kicks Off Phase 1 Trial in U.S.; Oral Amylin Peptide Aims for Differentiation – finance.biggo.com